TPI HLA-DR1 corresponds to a peptide segment derived from triosephosphate isomerase designed for HLA-DR1 binding research. The sequence contains residues contributing to MHC class II anchoring and stability. Researchers use it to examine antigen presentation, peptide-MHC conformation, and epitope mapping. Its defined structure supports detailed immunochemical analysis.
CAT No: ta-031
TPI HLA-DR1 is a synthetic peptide that corresponds to a defined epitope derived from the human triosephosphate isomerase (TPI) protein, presented in the context of the HLA-DR1 major histocompatibility complex class II molecule. As a biochemically characterized peptide, it plays a significant role in immunological research, particularly in studies focused on antigen presentation, T cell recognition, and autoimmune mechanisms. Its precise sequence and defined MHC restriction make it a valuable reagent for dissecting peptide-MHC interactions and for modeling immune responses in vitro. The utility of TPI HLA-DR1 extends to a range of experimental platforms, supporting both fundamental and translational research in immunology.
Antigen presentation research: TPI HLA-DR1 is widely employed in the investigation of peptide binding and presentation by HLA-DR1 molecules. By serving as a model epitope, it enables researchers to assess the structural and biochemical determinants of peptide-MHC class II interactions. This is critical for elucidating the rules governing antigen processing and presentation, as well as for evaluating the influence of peptide sequence variations on MHC binding affinity and stability. Such studies contribute to a deeper understanding of immune recognition mechanisms at the molecular level.
T cell activation assays: The peptide is frequently utilized in functional assays designed to measure CD4+ T cell responses. When loaded onto antigen-presenting cells expressing HLA-DR1, it can stimulate specific T cell clones or hybridomas, permitting analysis of T cell receptor (TCR) specificity, activation thresholds, and cytokine production profiles. These assays are fundamental for characterizing T cell repertoires, mapping immunodominant regions within antigens, and investigating tolerance or autoimmunity in controlled experimental systems.
Autoimmunity modeling: TPI HLA-DR1 serves as a valuable tool for modeling autoimmune responses in vitro, especially in the context of diseases where TPI is implicated as an autoantigen. By providing a defined peptide-MHC combination, it allows researchers to dissect the pathways leading to autoreactive T cell activation, analyze the breakdown of self-tolerance, and evaluate the contribution of specific epitopes to disease pathogenesis. Such studies are instrumental in uncovering the molecular underpinnings of autoimmunity and in identifying potential targets for intervention.
Peptide-MHC binding assays: The defined nature of this peptide enables its use in quantitative assays that measure the binding affinity and kinetics of peptide-MHC class II interactions. These assays are essential for validating computational predictions of peptide binding, optimizing peptide-based vaccine candidates, and benchmarking the performance of MHC binding algorithms. By providing a reproducible standard, the peptide supports the development of robust, high-throughput screening platforms for immunological research.
Structural biology studies: TPI HLA-DR1 is also employed in structural analyses aimed at resolving the three-dimensional architecture of peptide-MHC complexes. Its well-characterized sequence and binding properties make it suitable for crystallization and structural determination by X-ray crystallography or cryo-electron microscopy. Such structural insights are crucial for understanding the molecular basis of antigen recognition, informing rational design of immunotherapeutic agents, and guiding the development of next-generation immunomodulatory strategies.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More